GENFIT Secures $185M Funding to Advance Breakthrough Treatments for Liver Diseases

GENFIT, a pioneering late-stage biopharmaceutical firm committed to transforming the lives of patients with rare and severe liver diseases, has successfully raised $185 million in its latest funding round. With over two decades of expertise in liver disease research and development, GENFIT is at the forefront of addressing high unmet medical needs, underscored by the recent positive 52-week results from its Phase 3 trial (ELATIVE®) of elafibranor for Primary Biliary Cholangitis (PBC). This significant new capital will be directed towards advancing GENFIT’s diverse research and development pipeline, further bolstering its ongoing efforts in several critical therapeutic areas. Notably, the company has five programs currently in clinical stages addressing acute on chronic liver failure (ACLF), including therapeutic initiatives for hepatic encephalopathy. Additionally, GENFIT is making strides with a Phase 2 clinical program targeting cholangiocarcinoma and innovative preclinical initiatives aimed at urea cycle disorders and organic acidemias. The strategic use of these funds will ensure the continued progress of GENFIT’s diagnostic franchise focused on Metabolic dysfunction-associated steatohepatitis (MASH), further positioning the company as a leader in the field. With facilities located in Lille and Paris, France, Zurich, Switzerland, and Cambridge, MA, USA, GENFIT is not just a company; it is a beacon of hope for patients suffering from complex liver conditions. Publicly traded on both the Nasdaq Global Select Market and Euronext Paris, GENFIT's commitment to innovation and excellence remains steadfast as it embarks on this new chapter of growth and discovery.